Evidence map›Paper›PMID 40823720›Full record

ArticleCarcinogenesis2025

Core transcriptional regulatory circuit-regulated IGF2BP3 stabilizes E2F2 mRNA via m6A modification in neuroblastoma.

Pengcheng Yang, Jianwei Wang, Ziheng Wu, Ran Zhuo, Yanling Chen, Gen Li, Yanfang Tao, Xiaolu Li, Fang Fang, Di Wu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Carcinogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Pengcheng YangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.ORCID 0009-0002-5112-7821
Jianwei WangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.ORCID 0000-0002-9765-3264
Ziheng WuInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Ran ZhuoInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Yanling ChenInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Gen LiInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Yanfang TaoInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Xiaolu LiInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.ORCID 0000-0002-3892-495X
Fang FangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Di WuInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.ORCID 0000-0002-2364-850X
Yang YangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Hongli YinInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Guanghui QianInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Hairong WangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Xin LiCardiothoracic Surgery Department, Children's Hospital of Soochow University, Suzhou, Jiangsu 215025, China.
Juanjuan YuInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Randong YangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Yunyun XuInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Zhiheng LiInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.
Lei ShiDepartment of Medicinal Chemistry, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.
Zimu ZhangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.ORCID 0000-0002-7791-4252
Jian PanInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.ORCID 0000-0002-0292-5141
Jian WangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou 215003, China.

Funding

Jiangsu Province BE2021654Jiangsu Province BE2021657Jiangsu Province BE2022732Jiangsu Provincial Health Commission H2023142Jiangsu Provincial Health Commission Z2022031National Key R&D Program of China 2022YFC2502700National Natural Science Foundation 82072767National Natural Science Foundation 82141110National Natural Science Foundation 82203442National Natural Science Foundation 82373414Natural Science Foundation of Jiangsu Province BK20220047Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX23_3266Suzhou Health Talent Training Project GSWS2020047Suzhou Health Talent Training Project GSWS2021028Suzhou "Science, Education and Strong Health" Project QNXM2024026the Science and Technology Development Project of Suzhou City SKJY2021109the Science and Technology Development Project of Suzhou City SKJY2021111the Science and Technology Development Project of Suzhou City SKJY2021112the Science and Technology Development Project of Suzhou City SKY2022170the Science and Technology Development Project of Suzhou City SKY2022175
6 · The paper itself

Abstract

Neuroblastoma (NB) is a pediatric tumor with diverse outcomes and unknown underlying mechanisms. The core transcriptional regulatory circuit (CRC) and N6-methyladenosine (m6A) are key factors that control cell identity and fate. IGF2BP3 is an m6A reader protein that is transcriptionally regulated by CRC transcription factors (TFs). In NB, this molecule is abundantly expressed, and there is a clear correlation between its expression and a bad prognosis. We mechanistically demonstrated that IGF2BP3 promotes E2F2 mRNA expression through m6A, which is correlated with high risk and poor prognosis in NB patients. We showed that the CRC TF-IGF2BP3-E2F2 regulatory axis forms an oncogenic network that drives NB development and progression. Overall, we investigated the molecular mechanism by which IGF2BP3, a m6A-reading protein that is regulated by CRC TFs, regulates E2F2 mRNA expression in an m6A-dependent manner. This study highlights the therapeutic potential of disrupting this axis with m6A-targeted interventions.

Indexed as

AdenosineE2F2 Transcription FactorGene Expression Regulation, NeoplasticGene Regulatory NetworksNeuroblastomaRNA-Binding ProteinsRNA, MessengerAnimalsCell Line, TumorCell ProliferationHumansMicePrognosisRNA StabilityAdenosineE2F2 protein, humanE2F2 Transcription FactorIGF2BP3 protein, humanN-methyladenosineRNA-Binding ProteinsRNA, Messengercore transcriptional regulatory circuit (CRC)m6A readermRNA stabilityN6-methyladenosine (m6A)neuroblastoma

Identifiers

PMID40823720
PMCPMC12477426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.